RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) (“the Company” or “RegeneRx”), a clinical-stage drug development company focused on tissue protection, repair and regeneration issued an advisory on its dry eye syndrome Phase 3 clinical trial. To access the advisory, go to the following link: http://www.regenerx.com/2020-03-18-Ma
March 18, 2020
· 2 min read